Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration – Business Wire

Leave a Comment / Mega Deals / By

Repare Therapeutics Announces buyout of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration  Business Wire

Source: news.google.com

Related Posts

Leave a Comment

Your email address will not be published. Required fields are marked *